Benefits research studies show employers expect to lay out 7% more in healthcare costs in 2014, a move that has not been accompanied by lower employee costs.
The National Coalition on Health Care took aim at co-pay cards and coupons with a report suggesting that they might push 2 million US seniors to opt for more expensive branded drugs over generics.
Last year, a wave of new products brought the industry succor as it awaits the full impact of the patent cliff on blockbuster brands. But companies should brace for contraction.
Consumer advocacy group Community Catalyst declared war on prescription co-pay cards and coupons, saying the sales tools are nothing more than kickbacks and bribes.
Co-pay cards have proliferated, undermining payer benefit plans. Now, insurers are striking back against the cards.
Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.